Milk Thistle (Silybum marianum) Seed Extract — 200 mg (yielding 160 mg Silymarin) Silybum marianum seed extract, standardized to 80% silymarin — the flavonolignan complex comprising silybin, silydianin, silychristin, and isosilybin, with silybin recognized as the most hepatoprotective individual constituent — provides the formula's primary hepatocellular membrane stabilization, antioxidant, and regenerative support. Silymarin modifies the lipid composition and structural integrity of hepatocyte outer membranes, reducing permeability to hepatotoxic compounds, while simultaneously providing potent free radical scavenging protection against reactive intermediates generated during Phase I CYP450 biotransformation. Silybin specifically stimulates RNA polymerase I-dependent ribosomal RNA synthesis in hepatocytes, promoting hepatocellular protein synthesis and regeneration, and supports intrahepatic glutathione levels — providing the direct antioxidant substrate replenishment that protects liver cells from the oxidative burden inherent to high-throughput toxin processing.
N-Acetyl Cysteine — 50 mg N-Acetyl Cysteine is the most bioavailable oral precursor to L-cysteine — the rate-limiting amino acid for intracellular glutathione biosynthesis — directly replenishing hepatocellular glutathione stores depleted by chronic toxin processing and Phase I-generated reactive electrophilic intermediates. Within the Phase II glutathione conjugation pathway — the liver's primary detoxification route for reactive electrophiles, heavy metals, and xenobiotics — glutathione provides the nucleophilic thiol group that conjugates with and neutralizes toxic intermediates for safe biliary or urinary excretion, with adequate glutathione availability being the rate-limiting determinant of this pathway's capacity. NAC's role as the primary pharmaceutical antidote for acetaminophen overdose-induced hepatotoxicity — which operates through glutathione depletion — underscores its central clinical importance as a hepatoprotective glutathione precursor, making it an indispensable inclusion in any comprehensive Phase II detoxification support formula.
L-Methionine — 100 mg L-Methionine is an essential sulfur-containing amino acid that serves as the direct precursor to S-adenosylmethionine (SAMe) — the universal methyl donor for the methylation Phase II conjugation pathway — through which the liver methylates and neutralizes a broad spectrum of substrates including catecholamines, estrogens, histamine, and various xenobiotics for safe elimination. Beyond its methylation pathway role, L-Methionine's sulfur content is transsulfurated to cysteine through the transsulfuration pathway, contributing to glutathione biosynthesis and the sulfation Phase II conjugation pathway — providing dual detoxification pathway support through a single amino acid. L-Methionine additionally supports hepatic fat metabolism through its role as a lipotropic agent, promoting phosphatidylcholine synthesis and reducing the accumulation of hepatic fat associated with suboptimal methylation capacity.
DIM® (Diindolylmethane) — 25 mg DIM® (BioResponse LLC, US Patent #6,086,915) is a proprietary bioavailability-enhanced diindolylmethane complex — the primary bioactive indole metabolite of cruciferous vegetable indole-3-carbinol — that uniquely supports both Phase I and Phase II hepatic detoxification, making it the only ingredient in this formula with documented activity across both detoxification phases. In Phase I, DIM® modulates CYP1A1 and CYP1A2 enzyme induction to support the 2-hydroxylation of estrogens — redirecting estrogen metabolism toward the less estrogenic 2-hydroxyestrone pathway and away from the more biologically active 16α-hydroxyestrone. In Phase II, DIM® supports glucuronidation and sulfation of estrogen metabolites for elimination, providing comprehensive estrogen detoxification support from enzymatic processing through final conjugation and excretion — making this formula particularly relevant for clients in hormonal clearance and estrogen metabolism support protocols.
